EGFR and lung adenocarcinoma: The First-SIGNAL study comparing the efficacy of single-agent gefitinib with gemcitabine plus cisplatin as first-line therapy for Korean ‘never-smokers’ with stage IIIB or IV lung adenocarcinoma not selected by EGFR mutation status [114] was unable to demonstrate superiority for gefitinib over chemotherapy.